Study design and participants
Eligible participants were healthy controls (HC; n=57) and people living with HIV (PLHIV; n=58) who had received two vaccine doses and fulfilled the study inclusion criteria including baseline and 6-month screenings for negativity for SARS-CoV-2 exposures. As described earlier, all participants seroconverted during the one-month follow-up (day 35) i.e.,14 days after dose 2 in both groups (Demographics and medical report of study participants.Mann–Whitney U test was applied to compare the continuous variables and XVirological data, serum and saliva antibody status of study participants.Mann–Whitney U test was applied to compare the continuous variables and X